|Targets||Hsp90 | HSP|
|Description||Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, H2O-soluble Hsp90 inhibitor with IC50 of 62 nM.17-DMAG displays ~2 times potency against human Hsp90 than 17-AAG, with IC50 of 62 nM versus 119 nM. In SKBR3 and SKOV3 cells which over-express Hsp90 client protein Her2, 17-DMAG causes down-regulation of Her2 with EC50 of 8 nM and 46 nM, respectively, as well as induction of Hsp70 with EC50 of 4 nM and 14 nM, respectively, leading to significant cytotoxicity with GI50 of 29 nM and 32 nM, respectively, consistent with Hsp90 inhibition. 17-DMAG in combination with vorinostat synergistically induces apoptosis of the cultured MCL cells as well as primary MCL cells, more potently than either agent alone, by markedly attenuating the levels of cyclin D1 and CDK4, as well as of c-Myc, c-RAF and Akt. 17-DMAG treatment at 5 mg/kg or 25 mg/kg thrice per week significantly reduces tumor growth of TMK-1 xenografts, by significantly reducing vessel area and numbers of proliferating tumor cells in sections. Consistent the inhibition of FAK signaling in vivo, 17-DMAG treatment at 25 mg/kg three times a week significantly suppresses tumor growth, and metastasis of ME180 and SiHa xenografts in mice. Administration of 17-DMAG at 10 mg/kg for 16 days significantly decreases the white blood cell count and prolongs the survival in a TCL1-SCID transplant mouse model.|
|Brife Description||Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, H2O-soluble Hsp90 inhibitor, IC50 62 nM.|
|Synonyms||17-DIMETHYLAMINOETHYLAMINO-17-DEMETHOXYG; 17-DMAGhydrochloride; 17-[2-(Dimethylamino)ethylamino]-17-desmethylgeldanamycin; 17-Demethoxy-17-[[2-(dimethylamino)ethyl]amino]geldanamycin; Alvespimycin; 17-DMAG (Alvespimycin)|
|Solubility||DMSO: >25 mg/mL|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibi...
17-AAG hydrochloride is a potent HSP90 inhibitor with IC50 value of 5 nM, which is a 100-fold higher binding affinity for HSP90 derived from tumour cells than t...
BIIB021 is An orally active, purine-scaffold, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. BIIB021 that is ...
MPC-0767 is a novel L-alanine ester pro-drug of MPC-3100, designed to have improved aqueous solubility compared to MPC-3100.
Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, H2O-soluble Hsp90 inhibitor with IC50 of 62 nM.17-DMAG displays ~2 times potency against human Hsp90 t...
PF-04929113, also known as SNX-5422; is a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although t...
Debio 0932, also known as CUDC-305, is a novel Hsp90 inhibitor with strong affinity for Hsp90 alpha/beta, high oral bioavailability and potent anti-proliferativ...
Geldanamycin is a benzoquinone ansamycin antibiotic that binds to Hsp90 (Heat Shock Protein 90) and inhibits its function. Hsp90 client proteins play important ...
Pochocin D is a patent Hsp90 inhibitor. IC50 80.0nM.
TAS-116 is a inhibitor of Hsp90. It induces significant cytotoxicity in MM cells even in the presence of BMSCs, associates with downregulation of phospho-Akt an...
An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhi...
VER-49009 a protein 90 (HSP90) inhibitor(IC50= 47 nM).
ML346, a barbituric acid skeleton compound, is a novel activator of Hsp70 which could induce HSF-1-dependent chaperone expression and repair protein folding in ...
VER-155008 is an adenosine-derived inhibitor of heat shock protein 70 (Hsp70; IC50 = 0.5 µM) that is selective over Hsp90.It targets the nucleotide-binding doma...
Geranylgeranylacetone is commonly utilized to protect the gastric mucosa in peptic ulcer disease can induce expression of HSP70, HSPB8, and HSPB1.
MPC-3100 targets the N-terminal ATP-binding site of Hsp90 and blocks the activity of ATPase. In the Her2-luciferase degradation assay, MPC-3100 reduces this cli...
KIN1148, a small-molecule IRF3 agonist, associates with and activates recombinant RIG-I protein in cell-free assays. KIN1148 is a novel influenza vaccine adjuva...
Chlorobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 60μmol/...
PF-4942847 is a novel oral Hsp90 inhibitor, which is a candidate for clinical development in TNBC by collaboratively targeting multiple signaling pathways. In a...
Ganetespib, also known as STA-9090, is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhib...